Proactive Investors - Run By Investors For Investors

ReNeuron Group's phase IIb stroke trial kicks off with first patient treated

ReNeuron Group PLC’s (LON:RENE) Michael Hunt tells Proactive London's Andrew Scott the first person has now been treated in the US phase IIb clinical study of their CTX stem cell therapy candidate for stroke disability.

The mid-stage trial, called PISCES III, will see 110 patients with stable post-stroke disability given either the CTX therapy or a placebo.

ReNeuron wants to show that the patients on its treatment see a “clinically significant” improvement on the Modified Rankin Scale – a measure of disability and dependence – after six months.

Top-line results are due early next year.

 
Meet Yellow Cake PLC, Avation PLC, Manolete Partners PLC and Crossword Cybersecurity Plc at our event, London , 05 September 2019. Register here »
View full RENE profile View Profile

ReNeuron Group PLC Timeline

© Proactive Investors 2019

Proactive Investors Limited, trading as “Proactiveinvestors United Kingdom”, is Authorised and regulated by the Financial Conduct Authority.
Registered in England with Company Registration number 05639690. Group VAT registration number 872070825 FCA Registration number 559082. You can contact us here.

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use